LienTeh.net > Ads > Acaluni (Acalabrutinib)

Acaluni (Acalabrutinib)

Inquire / Price

Model Number：

RL14202309011310
Brand Name：

Acaluni
Origin：

Generic drug, LAOS.
Small Orders：

Small order has available
Tags：

Mantle Cell Lymphoma（MCL） small lymphocytic lymphoma (SLL) Chronic lymphocytic leukemia (CLL)

Inquire Now Link

Poster

Details
Description

Packaging Size

60C/bottle
Strength

100mg
Compositon

Acalabrutinib
Treatment

Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL),Mantle Cell Lymphoma（MCL）
Form

Capsule
Brand

Acaluni
Quantity Unit

100mg*60C/bottle
Manufacturer

Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）

Contents hide

1 Mantle Cell Lymphoma

2 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

2.1 Monotherapy

2.2 Combination with obinutuzumab

2.2.1 Cycle 1

2.2.2 Cycle 2

2.2.3 Cycles 3-7

2.2.4 Cycle 8 and subsequent cycles

Acalabrutinib is used to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used alone or with obinutuzumab (Gazyva) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL: a type of cancer that begins in the white blood cells). Acalabrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

ADULT

Mantle Cell Lymphoma

Indicated for mantle cell lymphoma (MCL) in patients who have received ≥1 prior therapy

100 mg PO q12hr

Continue until disease progression or unacceptable toxicity

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Indicated for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Monotherapy

100 mg PO q12hr
Continue until disease progression or unacceptable toxicity

Combination with obinutuzumab

Indicated for patients with previously untreated CLL or SLL
Start acalabrutinib at Cycle 1 (each cycle is 28 days)
Start obinutuzumab at Cycle 2 for a total of 6 cycles
Refer to obinutuzumab for infusion rates
Cycle 1
- Days 1-28: Acalabrutinib 100 mg PO q12hr
Cycle 2
- Days 1-28: Acalabrutinib 100 mg PO q12hr
- Day 1: Obinutuzumab 100 mg IV infusion
- Day 2: Obinutuzumab 900 mg IV infusion
- Days 8 and 15: Obinutuzumab 1000 mg IV infusion
Cycles 3-7
- Day 1-28: Acalabrutinib 100 mg PO q12hr
- Day 1: Obinutuzumab 1000 mg IV infusion
Cycle 8 and subsequent cycles
- Day 1-28: Acalabrutinib 100 mg PO q12hr
- Continue until disease progression or unacceptable toxicity